{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-122241","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.481820+00:00","generated_at":"2026-06-07T19:51:21.482006+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AbbVie to acquire ImmunoGen for $31.26/share ($10.1B total) – adds ovarian cancer therapy ELAHERE","bullets":["Transaction valued at $31.26 per share in cash, total equity value approx $10.1B.","Premium of ~95% to ImmunoGen's closing price on Nov 29, 2023.","Expected to close mid-2024; negatively impact 2024 EPS by ~$0.13, 2025 by ~$0.16, accretive from 2027.","Key asset: ELAHERE, a first-in-class ADC approved for platinum-resistant ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-122241","json":"https://secwatch.observer/filing/0001104659-23-122241.json","markdown":"https://secwatch.observer/filing/0001104659-23-122241.md","text":"https://secwatch.observer/filing/0001104659-23-122241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/0001104659-23-122241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/tm2331814d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:51:21.482006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}